Lack of standardized therapeutic approaches is arguably the significant contributor to the high burden of mortality observed in the ongoing pandemic of the Coronavirus disease, 2019 (COVID-19). Evidence is accumulating on SARS-CoV-2 specific immune cell dysregulation and consequent tissue injury in COVID-19. Currently, no definite drugs or vaccines are available against the disease; however initial results of the ongoing clinical trials have raised some hope. In this article, taking insights from the emerging empirical evidence about host-virus interactions, we deliberate upon plausible pathogenic mechanisms and suitable therapeutic approaches for COVID-19.
All Keywords
【저자키워드】 SARS-CoV-2, Immunopathogenesis, therapeutic strategy, betacoronaviruses, anti-virals,
【저자키워드】 SARS-CoV-2, Immunopathogenesis, therapeutic strategy, betacoronaviruses, anti-virals,